these warrants were valued at $ 20,092 using the black-scholes option pricing model using the following assumptions : three year term , $ 2.10 stock price , $ 2.40 exercise price , 236 % volatility , 0.99 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 2.40 per share . on september 26 , 2014 , the company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $ 688,970 . these warrants were valued at $ 103,223 using the black-scholes option pricing model using the following assumptions : three year term , $ 4.45 stock price , $ 3 exercise price , 235 % volatility , 1.08 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 3 per share . on october 1 , 2014 , 25,000 of the remaining 175,000 warrants with variable vesting dates , issued march 20 , 2013 , vested . the 25,000 warrants were valued at $ 104,281 using the black-scholes option pricing model using the following assumptions : three-year term , $ 4.21 stock price , $ 2.47 exercise price , 235 % volatility , 1.0 % risk free rate . the company carried out a re-measurement of the valuation of the unvested warrants as at december 31 , 2014 , in accordance with asc 505. the company estimated that vesting of the unvested warrants will take place over the three years story_separator_special_tag this annual report on form 10-k contains forward-looking statements . these forward-looking statements are not historical facts but rather are based on current expectations , estimates and projections . we may use words such as anticipate ,  expect ,  intend ,  plan ,  believe ,  foresee ,  estimate and variations of these words and similar expressions to identify forward-looking statements . these statements are not guarantees of future performance and are subject to certain risks , uncertainties and other factors , some of which are beyond our control , are difficult to predict and could cause actual results to differ materially from those expressed or forecasted . you should read this report completely and with the understanding that actual future results may be materially different from what we expect . the forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this report . we will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements , whether as a result of new information , future events or otherwise . the following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financial information included elsewhere in this report . overview we are a clinical-stage life sciences company focused on developing blood based diagnostic tests that meet the need for accurate , fast , cost effective and scalable tests for detecting and diagnosing cancer and other diseases . we have developed twenty eight blood-based assays to date to detect specific biomarkers that can be used individually or in combination to generate a profile which forms the basis of a test for a particular cancer or disease . we intend to commercialize our products in the future through various channels within the european union , the united states and throughout the rest of the world likely beginning with china and india . we are developing blood-based diagnostics for the most prevalent cancers , beginning with colorectal , lung and pancreatic cancer , using our nucleosomics ® biomarker discovery platform . the platform employs a range of simple nuq ® immunoassays on an industry standard elisa format , which allow rapid quantification of epigenetic changes in biofluids ( whole blood , plasma , serum , sputum , urine etc . ) compared to other approaches such as bisulfite conversion and polymerase chain reaction , or pcr . nuq ® biomarkers can be used alone , or in combination to generate profiles related to specific conditions . the first tranche of data released from a large independent trial for colorectal cancer could , if carried through into our screening or symptomatic trials , potentially have a positive impact for broad scale , cost effective , cancer diagnostics . management has identified the specific processes and resources required to achieve the near and medium term objectives of the company 's business plan , including personnel , facilities , equipment , research and testing materials including antibodies and clinical samples , and the protection of intellectual property . to date , operations have proceeded satisfactorily in relation to the business plan . however it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost . it is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required . such events could result in delays to the achievement of the near and medium term objectives of the business plan , in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the ivd market . we do not anticipate earning significant revenues until such time as we are able to fully market our intended products on the ivd market . for this reason , our auditors stated in their report on our most recent audited financial statements that our losses and negative cash flow from operations raise substantial doubt that we will be able to continue as a going concern without further financing . our ability to continue as a going concern is dependent upon our ability story_separator_special_tag these warrants were valued at $ 20,092 using the black-scholes option pricing model using the following assumptions : three year term , $ 2.10 stock price , $ 2.40 exercise price , 236 % volatility , 0.99 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 2.40 per share . on september 26 , 2014 , the company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $ 688,970 . these warrants were valued at $ 103,223 using the black-scholes option pricing model using the following assumptions : three year term , $ 4.45 stock price , $ 3 exercise price , 235 % volatility , 1.08 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 3 per share . on october 1 , 2014 , 25,000 of the remaining 175,000 warrants with variable vesting dates , issued march 20 , 2013 , vested . the 25,000 warrants were valued at $ 104,281 using the black-scholes option pricing model using the following assumptions : three-year term , $ 4.21 stock price , $ 2.47 exercise price , 235 % volatility , 1.0 % risk free rate . the company carried out a re-measurement of the valuation of the unvested warrants as at december 31 , 2014 , in accordance with asc 505. the company estimated that vesting of the unvested warrants will take place over the three years story_separator_special_tag this annual report on form 10-k contains forward-looking statements . these forward-looking statements are not historical facts but rather are based on current expectations , estimates and projections . we may use words such as anticipate ,  expect ,  intend ,  plan ,  believe ,  foresee ,  estimate and variations of these words and similar expressions to identify forward-looking statements . these statements are not guarantees of future performance and are subject to certain risks , uncertainties and other factors , some of which are beyond our control , are difficult to predict and could cause actual results to differ materially from those expressed or forecasted . you should read this report completely and with the understanding that actual future results may be materially different from what we expect . the forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this report . we will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements , whether as a result of new information , future events or otherwise . the following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financial information included elsewhere in this report . overview we are a clinical-stage life sciences company focused on developing blood based diagnostic tests that meet the need for accurate , fast , cost effective and scalable tests for detecting and diagnosing cancer and other diseases . we have developed twenty eight blood-based assays to date to detect specific biomarkers that can be used individually or in combination to generate a profile which forms the basis of a test for a particular cancer or disease . we intend to commercialize our products in the future through various channels within the european union , the united states and throughout the rest of the world likely beginning with china and india . we are developing blood-based diagnostics for the most prevalent cancers , beginning with colorectal , lung and pancreatic cancer , using our nucleosomics ® biomarker discovery platform . the platform employs a range of simple nuq ® immunoassays on an industry standard elisa format , which allow rapid quantification of epigenetic changes in biofluids ( whole blood , plasma , serum , sputum , urine etc . ) compared to other approaches such as bisulfite conversion and polymerase chain reaction , or pcr . nuq ® biomarkers can be used alone , or in combination to generate profiles related to specific conditions . the first tranche of data released from a large independent trial for colorectal cancer could , if carried through into our screening or symptomatic trials , potentially have a positive impact for broad scale , cost effective , cancer diagnostics . management has identified the specific processes and resources required to achieve the near and medium term objectives of the company 's business plan , including personnel , facilities , equipment , research and testing materials including antibodies and clinical samples , and the protection of intellectual property . to date , operations have proceeded satisfactorily in relation to the business plan . however it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost . it is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required . such events could result in delays to the achievement of the near and medium term objectives of the business plan , in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the ivd market . we do not anticipate earning significant revenues until such time as we are able to fully market our intended products on the ivd market . for this reason , our auditors stated in their report on our most recent audited financial statements that our losses and negative cash flow from operations raise substantial doubt that we will be able to continue as a going concern without further financing . our ability to continue as a going concern is dependent upon our ability

liquidity and capital resources as of december 31 , 2015 , the company had cash of $ 5,916,006 and prepayments and other current assets of $ 306,649. the company had current liabilities of $ 1,119,650. this represents a working capital surplus of $ 5,103,005. the company used $ 8,766,323 in net cash for the year ended december 31 , 2015 , compared to $ 4,140,825 for the year ended december 31 , 2014. the increase in cash used year over year was primarily due to an increase in research and development expenditure and legal costs associated with our up-listing onto the nyse mkt . please see results of operations ,  below for more detail . 33 net cash used in investing activities increased year over year by $ 49,254 to $ 352,243 in the 2015 period , mainly as a result of the purchase of the nucleosomics® wo2005019826 : detection of histone modifications in cell-free nucleosomes patent ( i.e . the patent that underlies the nuq ® -m tests ) from chroma therapeutics limited for $ 55,000. net cash provided by financing activities amounted to $ 12,882,602 for the year ended december 31 , 2015 , compared to $ 5,737,766 for the year ended december 31 , 2014. the company raised approximately $ 9.7 million in net proceeds in february 2015 , when approximately 2.8 million shares of common stock were issued in a public offering at the time of our up-listing to the nyse mkt . we also raised another $ 1.5 million from further issuances in a private placement during the first quarter of 2015 and approximately $ 1.3 million from exercises of warrants and stock options in 2015. a capital lease for three tecan machines resulted in an additional $ 223,152 being raised over this period . this resulted in an increase of cash of $ 3,777,042 for the year ended december 31 , 2015 , compared to an increase of $ 1,250,260 for the year ended december 31 , 2014. the company leases three tecan machines ( automated liquid handling robots ) under a lease classified as a capital lease .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources as of december 31 , 2015 , the company had cash of $ 5,916,006 and prepayments and other current assets of $ 306,649. the company had current liabilities of $ 1,119,650. this represents a working capital surplus of $ 5,103,005. the company used $ 8,766,323 in net cash for the year ended december 31 , 2015 , compared to $ 4,140,825 for the year ended december 31 , 2014. the increase in cash used year over year was primarily due to an increase in research and development expenditure and legal costs associated with our up-listing onto the nyse mkt . please see results of operations ,  below for more detail . 33 net cash used in investing activities increased year over year by $ 49,254 to $ 352,243 in the 2015 period , mainly as a result of the purchase of the nucleosomics® wo2005019826 : detection of histone modifications in cell-free nucleosomes patent ( i.e . the patent that underlies the nuq ® -m tests ) from chroma therapeutics limited for $ 55,000. net cash provided by financing activities amounted to $ 12,882,602 for the year ended december 31 , 2015 , compared to $ 5,737,766 for the year ended december 31 , 2014. the company raised approximately $ 9.7 million in net proceeds in february 2015 , when approximately 2.8 million shares of common stock were issued in a public offering at the time of our up-listing to the nyse mkt . we also raised another $ 1.5 million from further issuances in a private placement during the first quarter of 2015 and approximately $ 1.3 million from exercises of warrants and stock options in 2015. a capital lease for three tecan machines resulted in an additional $ 223,152 being raised over this period . this resulted in an increase of cash of $ 3,777,042 for the year ended december 31 , 2015 , compared to an increase of $ 1,250,260 for the year ended december 31 , 2014. the company leases three tecan machines ( automated liquid handling robots ) under a lease classified as a capital lease .
```    
 Suspicious Activity Report : these warrants were valued at $ 20,092 using the black-scholes option pricing model using the following assumptions : three year term , $ 2.10 stock price , $ 2.40 exercise price , 236 % volatility , 0.99 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 2.40 per share . on september 26 , 2014 , the company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $ 688,970 . these warrants were valued at $ 103,223 using the black-scholes option pricing model using the following assumptions : three year term , $ 4.45 stock price , $ 3 exercise price , 235 % volatility , 1.08 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 3 per share . on october 1 , 2014 , 25,000 of the remaining 175,000 warrants with variable vesting dates , issued march 20 , 2013 , vested . the 25,000 warrants were valued at $ 104,281 using the black-scholes option pricing model using the following assumptions : three-year term , $ 4.21 stock price , $ 2.47 exercise price , 235 % volatility , 1.0 % risk free rate . the company carried out a re-measurement of the valuation of the unvested warrants as at december 31 , 2014 , in accordance with asc 505. the company estimated that vesting of the unvested warrants will take place over the three years story_separator_special_tag this annual report on form 10-k contains forward-looking statements . these forward-looking statements are not historical facts but rather are based on current expectations , estimates and projections . we may use words such as anticipate ,  expect ,  intend ,  plan ,  believe ,  foresee ,  estimate and variations of these words and similar expressions to identify forward-looking statements . these statements are not guarantees of future performance and are subject to certain risks , uncertainties and other factors , some of which are beyond our control , are difficult to predict and could cause actual results to differ materially from those expressed or forecasted . you should read this report completely and with the understanding that actual future results may be materially different from what we expect . the forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this report . we will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements , whether as a result of new information , future events or otherwise . the following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financial information included elsewhere in this report . overview we are a clinical-stage life sciences company focused on developing blood based diagnostic tests that meet the need for accurate , fast , cost effective and scalable tests for detecting and diagnosing cancer and other diseases . we have developed twenty eight blood-based assays to date to detect specific biomarkers that can be used individually or in combination to generate a profile which forms the basis of a test for a particular cancer or disease . we intend to commercialize our products in the future through various channels within the european union , the united states and throughout the rest of the world likely beginning with china and india . we are developing blood-based diagnostics for the most prevalent cancers , beginning with colorectal , lung and pancreatic cancer , using our nucleosomics ® biomarker discovery platform . the platform employs a range of simple nuq ® immunoassays on an industry standard elisa format , which allow rapid quantification of epigenetic changes in biofluids ( whole blood , plasma , serum , sputum , urine etc . ) compared to other approaches such as bisulfite conversion and polymerase chain reaction , or pcr . nuq ® biomarkers can be used alone , or in combination to generate profiles related to specific conditions . the first tranche of data released from a large independent trial for colorectal cancer could , if carried through into our screening or symptomatic trials , potentially have a positive impact for broad scale , cost effective , cancer diagnostics . management has identified the specific processes and resources required to achieve the near and medium term objectives of the company 's business plan , including personnel , facilities , equipment , research and testing materials including antibodies and clinical samples , and the protection of intellectual property . to date , operations have proceeded satisfactorily in relation to the business plan . however it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost . it is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required . such events could result in delays to the achievement of the near and medium term objectives of the business plan , in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the ivd market . we do not anticipate earning significant revenues until such time as we are able to fully market our intended products on the ivd market . for this reason , our auditors stated in their report on our most recent audited financial statements that our losses and negative cash flow from operations raise substantial doubt that we will be able to continue as a going concern without further financing . our ability to continue as a going concern is dependent upon our ability story_separator_special_tag these warrants were valued at $ 20,092 using the black-scholes option pricing model using the following assumptions : three year term , $ 2.10 stock price , $ 2.40 exercise price , 236 % volatility , 0.99 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 2.40 per share . on september 26 , 2014 , the company issued 24,000 warrants to an agent as part remuneration in respect of the issuance of 300,000 shares for net proceeds of $ 688,970 . these warrants were valued at $ 103,223 using the black-scholes option pricing model using the following assumptions : three year term , $ 4.45 stock price , $ 3 exercise price , 235 % volatility , 1.08 % risk free rate . each warrant is exercisable immediately for three years at an exercise price of $ 3 per share . on october 1 , 2014 , 25,000 of the remaining 175,000 warrants with variable vesting dates , issued march 20 , 2013 , vested . the 25,000 warrants were valued at $ 104,281 using the black-scholes option pricing model using the following assumptions : three-year term , $ 4.21 stock price , $ 2.47 exercise price , 235 % volatility , 1.0 % risk free rate . the company carried out a re-measurement of the valuation of the unvested warrants as at december 31 , 2014 , in accordance with asc 505. the company estimated that vesting of the unvested warrants will take place over the three years story_separator_special_tag this annual report on form 10-k contains forward-looking statements . these forward-looking statements are not historical facts but rather are based on current expectations , estimates and projections . we may use words such as anticipate ,  expect ,  intend ,  plan ,  believe ,  foresee ,  estimate and variations of these words and similar expressions to identify forward-looking statements . these statements are not guarantees of future performance and are subject to certain risks , uncertainties and other factors , some of which are beyond our control , are difficult to predict and could cause actual results to differ materially from those expressed or forecasted . you should read this report completely and with the understanding that actual future results may be materially different from what we expect . the forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this report . we will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements , whether as a result of new information , future events or otherwise . the following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and other financial information included elsewhere in this report . overview we are a clinical-stage life sciences company focused on developing blood based diagnostic tests that meet the need for accurate , fast , cost effective and scalable tests for detecting and diagnosing cancer and other diseases . we have developed twenty eight blood-based assays to date to detect specific biomarkers that can be used individually or in combination to generate a profile which forms the basis of a test for a particular cancer or disease . we intend to commercialize our products in the future through various channels within the european union , the united states and throughout the rest of the world likely beginning with china and india . we are developing blood-based diagnostics for the most prevalent cancers , beginning with colorectal , lung and pancreatic cancer , using our nucleosomics ® biomarker discovery platform . the platform employs a range of simple nuq ® immunoassays on an industry standard elisa format , which allow rapid quantification of epigenetic changes in biofluids ( whole blood , plasma , serum , sputum , urine etc . ) compared to other approaches such as bisulfite conversion and polymerase chain reaction , or pcr . nuq ® biomarkers can be used alone , or in combination to generate profiles related to specific conditions . the first tranche of data released from a large independent trial for colorectal cancer could , if carried through into our screening or symptomatic trials , potentially have a positive impact for broad scale , cost effective , cancer diagnostics . management has identified the specific processes and resources required to achieve the near and medium term objectives of the company 's business plan , including personnel , facilities , equipment , research and testing materials including antibodies and clinical samples , and the protection of intellectual property . to date , operations have proceeded satisfactorily in relation to the business plan . however it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost . it is also possible that the results of some processes may not be as expected and that modifications of procedures and materials may be required . such events could result in delays to the achievement of the near and medium term objectives of the business plan , in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the ivd market . we do not anticipate earning significant revenues until such time as we are able to fully market our intended products on the ivd market . for this reason , our auditors stated in their report on our most recent audited financial statements that our losses and negative cash flow from operations raise substantial doubt that we will be able to continue as a going concern without further financing . our ability to continue as a going concern is dependent upon our ability

